Testing a new version of a white blood cell booster in healthy volunteers
Part of Blood & lymphatic clinical trials.
This study compares a new version of filgrastim (a medicine that helps your body make more white blood cells) with the approved original product. Healthy volunteers will receive both treatments to see if they work the same and are equally safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You are healthy, as confirmed by medical history, physical exam, and lab tests
- Your body weight is between 50 and 110 kg (about 110 to 242 pounds) and your body mass index (BMI) is between 18 and 30
- If you are a woman who can become pregnant, you must use highly effective birth control for the whole study
- You have no significant medical conditions, such as blood disorders, lung disease, autoimmune disease, or recent infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
This study tests a better way to collect white blood cells from healthy people who donate blood. It may help improve how reliably and safely white blood cells are collected for research or future treatments.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
Hear when a new Neutropenia (Low White Blood Cell Count) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.